Members of Premier applaud the Food and Drug Administration (FDA) for releasing revised draft guidance on the use of citizen petitions to delay the market entry of generic medications and biosimilars. As noted by the agency, it’s become all too common for meritless citizen petitions to be filed in a brazen attempt by incumbents to prevent generic and biosimilar competition. The net effect of these efforts is not consumer protection, but a continued stranglehold on market exclusivity that only yields higher prices for patients and payers. Premier further applauds the FDA for referring anticompetitive citizen petitions to the Federal Trade Commission (FTC), and for calling out offenders in the FDA’s annual report to Congress. Today’s announcement is an important step to deter gaming of the regulatory approval process, and is critical to the creation of a more competitive generics and biosimilars marketplace.
--By Blair Childs, Senior Vice President of Public Affairs, Premier
About Premier, Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,000 U.S. hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.